

12th June 2019

To,
The BSE Surveillance Department
BSE Limited
P. J. Towers, Dalal Street,
Mumbai - 400 001

Sub: Clarification on price movement

Dear Madam/Sir,

As you are aware, the Company has published the below note in the audited financial statements for the financial year ended on March 31, 2019 in relation to the discontinuation of one of its products, Antifoam ("Product").

"Note 4: Due to the global restructuring, the Company's agreement to sell one of their products namely Antifoam stands terminated with effect from 01 April 2019. The revenue from Antifoam for the year ended March 31, 2019 and quarter ended March 31, 2019 is Rs. 3,683.14 lakhs and Rs. 409.77 lakhs respectively and for year ended March 31, 2018 and quarter ended March 31, 2018 was Rs. 3,108.91 lakhs and Rs. 825.46 lakhs respectively."

The Company does not have any long term contract for the manufacture and supply of the Product which was being undertaken on a purchase order basis by the Company. The Company was undertaking the manufacture of this Product pursuant to a license agreement ("License Agreement") entered into between the Company and [Dow Silicones Corporation] ("Dow"). The Company received a notice from Dow on May 29, 2019 terminating the License Agreement which information was immediately made public by way of the aforementioned note in the audited financial statements for the financial year ended March 31, 2019.

Apart from the above, the Company does not believe that there is any other information which needs to be disclosed in terms of the SEBI LODR Regulations.

In our view, such discontinuation of the Product may have impacted the price movement in the securities of the Company.

Thanking you,

Yours faithfully,

For Multibase India Limited

Company Secretary



Multibase India limited